TACSTD2 and renal cell carcinoma: Our findings of TROP-2 expression across RCC subtypes aligns with previous large-scale tissue-based studies, including the work of Dum et al., which reported TROP-2 positivity in approximately 75% of pRCC cases based on immunohistochemistry [12, 22].